British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Source:
British Society for Rheumatology - BSR
Publisher:
British Society for Rheumatology (BSR)
Publication date:
21 August 2018

Abstract

The purpose of this guideline is to provide evidence-based recommendations for the safe use of biologic therapies in adults (aged >18 years). Although the majority of published safety data still concern the use of first-generation anti-TNF agents in RA, this guideline has been expanded from the previous to cover the safety aspects of all biologic therapies (approved by the National Institute for Health and Care Excellence (NICE) as of June 2016 for the treatment of RA, PsA and axial spondyloarthritis (SpA) including AS [referred to as inflammatory arthritis (IA) henceforth]. Therapies approved by NICE after June 2016, such as secukinumab, sarilumab and the Janus kinase inhibitors, are not included.